- This event has passed.
9th Advanced RWE Applications in Pharma
October 26, 2021 - October 28, 2021
Real-world evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real world into their development programs, drug developers can now improve their clinical trial success by identifying and retaining suitable patients through increased patient stratification.
These are exciting times to reunite at the 9th Advanced Real-World Evidence Applications in Pharma to discuss the efforts to advance real-world evidence’s effective generation and utilization.
The stage is set for a collaborative discussion platform bringing together you and other stakeholders from functions across clinical development, RWE, RWD, Data Science, Regulatory Affairs, Medical Affairs, HEOR, and many more!
Join us in October to overcome critical challenges in generating and implementing real-world evidence to enhance clinical R&D, support regulatory submission and decision-making, and ultimately drive commercial success.
Click here to download the event guide for the full agenda
What’s New in 2021?
2020 was an exciting year for real-world data (RWD) and real-world evidence (RWE) experts within pharma and biotech. The FDA’s high-profile acceptance of RWD as part of their review for COVID-19 treatments and vaccines for emergency use authorization was a big moment for the industry. This is now energizing RWD and RWE into R&D and clinical activities – expediting novel treatments for patients and substantially reducing drug developers’ R&D spend.
However, major questions still need answers urgently. The 9th Advanced Real-World Evidence Applications in Pharma will return in October 2021 to delve into the core industry challenges, including:
- Assessing the global regulatory environment for future RWE application
- Advanced data acquisition and analytics to enable your R&D and clinically informed decision making
- Leverage RWE in your clinical activities – from patient selection to synthetic trial arm
- How to create a robust, regulatory-compliant RWE framework and data package for your successful IND filing
- Maximizing your product lifecycle through a comprehensive observational data program
- Establishing pre-competitive collaboration to deepen your understanding of diseases, offering patients a personalized and effective treatment through RWE & RWD